Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Tagrisso Put on Priority Path in Japan for 1st-Line EGFR-Mutated NSCLC
February 6, 2018
- Japan Ethical Drug Market Projected at 9.6 Trillion Yen in 2024: Fuji Keizai
February 5, 2018
- Keiko Oishi to Head CMIC Holdings from April 1, with Pres. Nakamura Continuing as Chairman and CEO
February 5, 2018
- Drug Pricing Reform Could Cause “Crustal Change” in Industry Structure: Chugai President
February 2, 2018
- Chugai Notches Up Record Earnings in 2017 on Bullish Exports, Milestones
February 2, 2018
- Roche Diagnostics’ ALK CDx Ventana Filed for Add’l Use for Alecensa
February 2, 2018
- Meiji’s Parkinson’s Candidate Hits Goal in Japan PII/III, Filing Planned for 2018
February 2, 2018
- IMS Japan, Quintiles Japan to Change Names in April
February 1, 2018
- Astellas Taps EVP Yasukawa as Next CEO
February 1, 2018
- Hisamitsu’s Transdermal Schizophrenia Med Hits Primary Endpoint: US PIII
February 1, 2018
- Ferring Beefing Up Reproductive Health Biz in Japan, Sets Up Specialized Sales Team
January 31, 2018
- Sunovion’s Parkinson’s Candidate Hits PIII Primary Endpoint, US Filing Set for Spring
January 31, 2018
- Pfizer Files Japan NDA for Next-Gen ALK Inhibitor Lorlatinib
January 31, 2018
- US FDA Fast-Tracks Takeda’s Zika Vaccine Candidate
January 31, 2018
- Otsuka Bags US$10 Million Grant from Gates Foundation for Development of Anti-TB Drug
January 31, 2018
- Hiroshima Couple Served with Arrest Warrant over Counterfeit Harvoni
January 30, 2018
- Novartis Seeks Ankylosing Spondylitis Nod for Cosentyx in Japan
January 30, 2018
- New GSK Japan President to Take Office on Feb. 1
January 30, 2018
- Sanofi to Launch Antibody Drug Dupilumab for Atopic Dermatitis this Spring, Sets Up Special Marketing Force for Potential Blockbuster
January 30, 2018
- New PMP Scheme Will Cause “Pause” before PIII Go/No-Go Decision: Pfizer Japan Head
January 29, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…